Investigating the role of PSPC1 in treating acute myeloid leukemia.
Official title: Therapeutic value and mechanistic action of PSPC1 in AML
Funded at University of Texas Hlth Science Center · NIH-11094123 · Data updated 2026-11-12
This study is looking at a protein called PSPC1 to see how it affects the growth of acute myeloid leukemia (AML) cells, with the hope of finding new ways to treat patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $600,374 |
| NIH project number | 5R01CA285299-02 |
| Project ID | NIH-11094123 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who are seeking new treatment options.
✕Less likely to help
Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on understanding how the protein PSPC1 contributes to the development of acute myeloid leukemia (AML) and explores its potential as a therapeutic target. Researchers will investigate the effects of reducing PSPC1 levels on AML cell growth, differentiation, and survival. By using advanced laboratory techniques, they aim to uncover the mechanisms by which PSPC1 influences AML progression, which could lead to the development of new treatment strategies for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results in targeting similar molecular pathways in leukemia, indicating potential for success in this approach.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Xu, Mingjiang — University of Texas Hlth Science Center
- Study coordinator: Xu, Mingjiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.